AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06099535 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LNK01001 Dose B
Description: Capsules taken orally
Study NCT06099535 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: LNK01001 Dose B
Description: Capsules taken orally
Study NCT06099535 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Capsules taken orally
Study NCT05658068 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SAFE Spaces training and coaching
Description: Staff in facilities assigned to the intervention are eligible to receive evidence-based programming in suicide detection and prevention (Shield of Care; SOC) and wellness skill-building (Skills for Life) through training and personalized coaching. Multiple training sessions will be offered to small groups of staff in-person in residential facilities and paired with personalized in-person and virtual coaching.
Study NCT05916209 — intervention group
Intervention type: PROCEDURE
Intervention: Peripheral nerve blocks
Description: Peripheral nerve blocks provide intense, site-specific analgesia administring local anesthetics near the nerves.
Study NCT06101498 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Akut kidnet injury(AKI)
Description: postoperative 24 hours
Study NCT05318664 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cryotherapy
Description: 20 minutes of cryotherapy on the dominant shoulder with ice bags
Study NCT05948085 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zavegepant 10 mg IN
Description: All participants will receive zavegepant 10 mg IN spray in period 1 and a butterscotch candy + zavegepant 10 mg IN spray in period 2
Study NCT05884593 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Pedicle screw instrumentation using Mazor X robotic system
Description: Pedicle screw instrumentation using Mazor X robotic system
Study NCT04909944 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: i-gel Supraglottic insertion
Description: i-gel Supraglottic insertion for oxygenation
Study NCT04909944 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Laryngeal Tube Suction Disposable Supraglottic insertion
Description: Laryngeal Tube Suction Disposable Supraglottic insertion for oxygenation
Study NCT05216484 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 Vaccine, Inactivated (Vero Cell)
Description: the third dose immunization schedule of SARS-CoV-2 inactivated vaccine
Study NCT05143463 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NS101 IV infusion
Description: Approximately 1 hour prior to start of study drug infusion, an IV port will be inserted into the antecubital region and a sterile normal saline solution infusion will be initiated at fixed rate in order to keep the vein open. The study drug will be infused over approximately 60 minutes at a constant rate. At the end of the infusion, 3 mL of saline solution will be injected to flush the remaining drug into the IV catheter. The end of infusion will be set to the end of the 3 mL flush. For safety reason (e.g., administration of rescue medication), the IV line will remain opened for approximately 1 hour following completion of infusion.
Study NCT05143463 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: NS101 IV infusion
Description: Approximately 1 hour prior to start of study drug infusion, an IV port will be inserted into the antecubital region and a sterile normal saline solution infusion will be initiated at fixed rate in order to keep the vein open. The study drug will be infused over approximately 60 minutes at a constant rate. At the end of the infusion, 3 mL of saline solution will be injected to flush the remaining drug into the IV catheter. The end of infusion will be set to the end of the 3 mL flush. For safety reason (e.g., administration of rescue medication), the IV line will remain opened for approximately 1 hour following completion of infusion.
Study NCT06359899 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AK0901 capsule
Description: Active Substance: AK0901, Pharmaceutical Form: Capsule, Route of Administration: Oral
Study NCT06359899 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Active Substance: Placebo, Pharmaceutical Form: Capsule, Route of Administration: Oral
Study NCT06447636 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Surufatinib
Description: Surufatinib: 250mg qd，d1-21, q3w
Study NCT06447636 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab
Description: Sintilimab：200mg ivdrip, d1, q3w
Study NCT06447636 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: 130mg/m2，iv drip for 2h，d1, q3w
Study NCT06447636 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S1
Description: S1：40\~60mg Bid，d1\~14, q3w
Study NCT05210751 — intervention group
Intervention type: OTHER
Intervention: Physical and psychosocial assessments
Description: Dual Task Test, 6 min Walking Test, the Baecke Habitual Physical Activity Questionnaire, Multidimensional Fatigue Inventory-20, Tracking Test, General Self-Efficacy Scale the Toronto Alexithymia Scale, the Revised FM Impact Questionnaire, the Social Support Scale.
Study NCT05930886 — intervention group
Intervention type: OTHER
Intervention: Focus Group
Description: Black or Hispanic/Latino parents, caregivers or family members of children with ADHD symptoms and/or emotional dysregulation, will discuss: (1) impact of child's mental health, treatments, care received; (2) perceived and actual barriers to future study participation, including discussion about acceptability of bio-specimen collection methods for urine and blood. Each group will comprise individuals who self-identify as Hispanic/Latino, Black, or mixed race. Groups are anticipated to comprise individuals who identify with one or the the other race/ethnicity in order to create space to hear perspectives that may differ between these broadly defined groups.
Study NCT05782153 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Intervention A (hearing aid self-fitting with direct adjustment)
Description: The intervention offered is a hearing aid fitting with the Lexie B2 Powered by Bose receiver-in-the-canal hearing aids using a self-fitting strategy with direct adjustment. The hearing aids will be accompanied and operated with the Lexie smartphone application. Participants will complete a hearing screening (at 500, 1000, 2000 and 4000 Hz) called Hearing Check on the Lexie smartphone application, which will be used to tune the hearing aids according to frequency and loudness level. Participants will be able to use two wheels to change the loudness and fine-tune the hearing aids. Participants will wear the hearing aids for four weeks.
Study NCT05782153 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Intervention B (hearing aid self-fitting with in-situ fitting)
Description: The intervention offered is a hearing aid fitting with the Lexie B2 Powered by Bose receiver-in-the-canal hearing aids using the in-situ audiometry fitting strategy. The hearing aids will be accompanied and operated with the Lexie smartphone application. Participants will complete an in-situ audiogram on the Lexie app, which enables the measurement of hearing thresholds through the hearing aids (at 500, 1000, 2000 and 4000 Hz). The hearing aids will then be self-programmed according to the participant's in-situ audiogram with a proprietary fitting algorithm that is based on NAL-NL2. Participants will wear the hearing aids for four weeks.
Study NCT05673395 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electrolyzed alkaline reduced water generator
Description: Participants drink water (10 mL/kg body weight) generated from the device after intensive excercise.
Study NCT05673395 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Electrolyzed alkaline reduced water generator
Description: Participants drink water (10 mL/kg body weight) generated from the device after intensive excercise.
Study NCT06009757 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GUIDEX® guiding catheter
Description: The main steps of the procedure Percutaneous Coronary Intervention are :~* The patient should prepare for angioplasty using standard techniques. Appropriate anticoagulation and vasodilation therapy should be administered.~* The Guiding Catheter must be introduced into the vascular system by cut-down or percutaneous techniques.~* The guiding catheter will be introduce over a previously placed standard angiographic wire. It will be aspirate and flush after the removal of the angiographic wire following established angiographic technique.~* The catheter should should address the selected vascular site~* The guiding catheter will be removing. The procedure is performed in a healthcare facility, in an operating room under fluoroscopic monitoring. The users are trained practiticoners for PCI.
Study NCT06009757 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Launcher™ coronary guide catheter
Description: The main steps of the procedure Percutaneous Coronary Intervention are :~* The patient should prepare for angioplasty using standard techniques. Appropriate anticoagulation and vasodilation therapy should be administered.~* The Guiding Catheter must be introduced into the vascular system by cut-down or percutaneous techniques.~* The guiding catheter will be introduce over a previously placed standard angiographic wire. It will be aspirate and flush after the removal of the angiographic wire following established angiographic technique.~* The catheter should should address the selected vascular site~* The guiding catheter will be removing. The procedure is performed in a healthcare facility, in an operating room under fluoroscopic monitoring. The users are trained practiticoners for PCI.
Study NCT05244564 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Motion-assisted, Multi-modular Memory Desensitization and Reconsolidation (3MDR)
Description: Walk and talk therapy, walking on a treadmill while talking with a therapist about self-chosen pictures representative of one's trauma; 3MDR also includes some features of virtual reality exposure therapy (VRET) and Eye Movement Desensitization and Reprocessing (EMDR) therapy.
Study NCT05244564 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Motion-assisted, Multi-modular Memory Desensitization and Reconsolidation (3MDR)
Description: Walk and talk therapy, walking on a treadmill while talking with a therapist about self-chosen pictures representative of one's trauma; 3MDR also includes some features of virtual reality exposure therapy (VRET) and Eye Movement Desensitization and Reprocessing (EMDR) therapy.
Study NCT05377775 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Iliac Stenting
Description: Conventional Implantation of mesh stent in iliac stenosis with high-risk plaques
Study NCT06317532 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Lifestyle modification advice
Description: All female participants in groups A and B will be provided with lifestyle modification advice, including recommendations such as reducing caffeine intake, limiting salt consumption, decreasing animal fat consumption, quitting smoking, practicing relaxation techniques, applying heat when needed, considering the use of herbal agents, avoiding cold drinks and foods, and opting for loose, cotton clothing.
Study NCT06317532 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lifestyle modification advice
Description: All female participants in groups A and B will be provided with lifestyle modification advice, including recommendations such as reducing caffeine intake, limiting salt consumption, decreasing animal fat consumption, quitting smoking, practicing relaxation techniques, applying heat when needed, considering the use of herbal agents, avoiding cold drinks and foods, and opting for loose, cotton clothing.
Study NCT06317532 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Functional exercises
Description: Each female in group (B) will perform the exercise program three times a week for eight weeks at the University Women's Health Unit Exercise protocols mainly consist of relaxation, strengthening, stretching, aerobic exercises, pelvic floor muscle strengthening exercises, yoga, and Pilates
Study NCT05613348 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD19 CAR T-Cell(CAT19T2)
Description: Drug: Fludarabine， Administered intravenously Drug: Cyclophosphamide， Administered intravenously
Study NCT05493566 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Aldesleukin
Description: Given SC
Study NCT05493566 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV
Study NCT05808179 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Light
Description: Broad-spectrum white light flashes are \~4000 lux, 2 msec long, occur every 20 s
Study NCT05808179 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBT
Description: Cognitive behavioral therapy including psychoeducation, sleep hygiene, stimulus control, activity scheduling, motivational interviewing
Study NCT05808179 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CBT
Description: Cognitive behavioral therapy including psychoeducation, sleep hygiene, stimulus control, activity scheduling, motivational interviewing
Study NCT05808179 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sham Light
Description: Broad-spectrum white light flashes are \~4000 lux, 2 msec long, occur once
Study NCT05108545 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amphotericin B liposomes
Description: Amphotericin B liposomes for injection, 3 mg/kg, qd, IV
Study NCT04875559 — intervention group
Intervention type: OTHER
Intervention: Standardised multimodal pain treatment regimen
Description: Preoperatively:~* Paracetamol 1000 mg p.o.~* Celecoxib 400 mg p.o.~* Dexamethasone 12 mg p.o.~Perioperatively:~* Ondansetron 4 mg IV~* Bupivacaine 2.5 mg/mL, 20 mL LIA~* Oxycodone 0.15 mg/kg IV (Oxycodone 0.25 mg/kg for ALND)~Postoperatively:~* Paracetamol 1000 mg p.o. every 6h PRN~* Ibuprofen 400 mg p.o. every 6h (day 1-5) PRN~* Oxycodone 5 mg IV or 10 mg p.o. PRN~* Ondansetron 4 mg IV or p.o. PRN
Study NCT04347772 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Oral Nutrition Support
Description: Intensive Nutrition Intervention
Study NCT05332353 — intervention group
Intervention type: DRUG
Intervention: Bacillus Calmette-Guerin
Description: Bacillus Calmette-Guerin (BCG) is immunotherapy to prevent recurrence and progression of non muscle invasive bladder cancer.
Study NCT03811262 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ESP BLOCK
Description: local anesthetic will be injected between transverous process and erector spinae muscle
Study NCT03811262 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PECS BLOCK
Description: local anesthetic will be injected between pectoralis minor and pectoralis major (10 ml) and between pectoralis minor and serratus (20 ml)
Study NCT05446103 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood flow restriction training
Description: After warming up, the load is set at 80% of the predicted 1Repetition Maximum (RM) for elbow flexors. Following each successful repetition, the load is increased by 0.5 to 1kg until patients: fail to execute the exercise through the entire range of motion; used improper form to complete the repetition; needed assistance; reported pain. We will allow a 2-3 min of rest between each attempt to ensure recovery.~The session starts by calculating the arterial occlusion pressure in the standard anatomical position. Participants rest in the standing position for 3-5 minutes before measurement to ensure restoration of blood flow circulation and a cuff is placed in the most proximal part of their dominant upper-limb. BFR application is conducted by using an automatic personalized tourniquet system (Mad-Up Pro, France). An 40% occlusion pressure is set and subjects perform 4 sets of elbow flexion (30-15-15-15 reps) using 30% of 1 RM
Study NCT05446103 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Blood flow restriction training
Description: After warming up, the load is set at 80% of the predicted 1Repetition Maximum (RM) for elbow flexors. Following each successful repetition, the load is increased by 0.5 to 1kg until patients: fail to execute the exercise through the entire range of motion; used improper form to complete the repetition; needed assistance; reported pain. We will allow a 2-3 min of rest between each attempt to ensure recovery.~The session starts by calculating the arterial occlusion pressure in the standard anatomical position. Participants rest in the standing position for 3-5 minutes before measurement to ensure restoration of blood flow circulation and a cuff is placed in the most proximal part of their dominant upper-limb. BFR application is conducted by using an automatic personalized tourniquet system (Mad-Up Pro, France). An \<20% of occlusion pressure is set and subjects perform 4 sets of 10 reps of elbow flexion using 65% of 1 RM
Study NCT06235554 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Renal Stimulation
Description: Renal Denervation procedure as per hospital routine practice
Study NCT05265572 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Domestic Hygiene and household hygiene Intervention
Description: A demonstration on the domestic hygiene intervention will be conducted where participants will be guided on optimal cleaning of windowsills, floors and other surfaces with water and detergent, and advised on appropriate method of cleaning. Participants will be provided with a package of cleaning materials (mop, bucket, detergent, hand wash liquid soap and cloth for wet dusting) which will be used during the demonstration, and retained by participants to facilitate sustainability of the intervention during and after the study. Participants will be further engaged in an educational discussion, with the aid of a specially designed educational pamphlet containing information about health effects potentially associated with dust lead exposure from mine dumps and the personal hygiene and domestic hygiene steps that may be followed to reduce dust lead exposure.
Study NCT06160271 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PET scan of 68Ga-FAPI
Description: Use of a positron emission tomograph equipped with an X-ray scanner (PET/CT), essential for recording images after injection of a positron-emitting radiopharmaceutical (in this study, 68Ga-FAPI-46).
Study NCT04660045 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acalabrutinib
Description: Acalabrutinib, oral, 100 mg BID, continuous
Study NCT06222307 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Game-Based Exercises
Description: Week 1: Dough Kneading, Sorting Legumes, Cutting Lines with Scissors, Coloring with Dry Crayons Week 2: Dough Rolling, Scissor Use, Crumpling Paper, Finger Exercises, Tying Knots with Rubber Bands Week 3: Dough Cutting, Dough Rolling, Dough Stretching, Sewing with Needles, Wrapping Thread like a Spool, Sorting Legumes, Untying Knots in String Week 4: Rhythm Exercises, Dough Kneading and Rolling, Scissor Use, Sorting Legumes, Untying Knots in String Week 5: Stringing Beads on Thread, Unlocking, Tearing Paper, Sorting Legumes, Untying Knots in String Week 6: Tying Shoe Laces, Opening-Closing Jar Lids, Sorting Legumes
Study NCT06281899 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dapagliflozin 10 mg Tab
Description: Dapagliflozin 10 mg once daily
Study NCT06281899 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10 mg Tab
Description: Dapagliflozin 10 mg once daily
Study NCT06281899 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Low protein diet
Description: Plant based low protein diet (0.6 g/kg IBW)
Study NCT04781400 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mobile phone support
Description: Mobile phone support (SMS)
Study NCT06422533 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ceftolozane/tazobactam
Description: Ceftolozane/tazobactam 1.5 g tid IV infusion for 1 hour during 5 to 7 days
Study NCT06422533 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Piperacillin/tazobactam
Description: Piperacillin/tazobactam 4.5 g qid IV infusion for 30 minutes during 5 to 7 days
Study NCT05923996 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: microbotox
Description: Will be treated by single session of microbotox injection
Study NCT05923996 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: fractional carbon dioxide laser
Description: Two sessions of the fractional CO2 laser on this side of the face at 4-weeks intervals
Study NCT04781400 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Remote service delivery model
Description: ART treatment delivery via a courier service
Study NCT04781400 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Remote service delivery model
Description: ART treatment delivery via a courier service
Study NCT05573867 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical activity on prescription
Description: All participants, regardless of group affiliation, receive routine written and verbal information about PSF and information about recommended level of physical activity. Intervention group receive as add on individualized, digital coaching twice a week for 12 weeks with Physical activity on prescription (FaR) to increase physical activity and reduce PSF after stroke.
Study NCT06419400 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Supportive text messages
Description: The intervention group will receive a series of supportive text messages over the 6 month trial period, varying in content and frequency.
Study NCT05152420 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VMX-C001
Description: VMX-C001 is human factor X engineered to be insensitive to factor Xa DOACs
Study NCT05152420 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: VMX-C001 matched placebo
Study NCT05152420 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apixaban
Description: FXa Inhibitor